PTN Palatin Technologies Inc.

0.84
+0.03  (+4%)
Previous Close 0.81
Open 0.85
Price To Book 8.44
Market Cap 171405840
Shares 203,063,429
Volume 674,282
Short Ratio 25.9
Av. Daily Volume 734,234

SEC filingsSee all SEC filings

  1. EFFECT - Notice of Effectiveness 19600278
  2. 424B5 - Prospectus [Rule 424(b)(5)] 19597738
  3. 424B3 - Prospectus [Rule 424(b)(3)] 19597308
  4. 8-K - Current report 19587706
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 19585824

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date extended to June 23, 2019.
Vyleesi (Bremelanotide)
Female sexual dysfunction (FSD)
Phase 2 trial to commence 1H 2019.
PL-3994
Heart failure
Phase 1 data due 1Q 2019.
PL-8177
Inflammatory bowel diseases

Latest News

  1. Edited Transcript of PTN earnings conference call or presentation 12-Feb-19 4:00pm GMT
  2. Palatin Technologies, Inc. Reports Second Fiscal Quarter 2019 Results and Provides Corporate Update
  3. Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on February 12, 2019
  4. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
  5. Palatin Technologies, Inc. (PTN): Hedge Fund Sentiment Unchanged
  6. Edited Transcript of PTN earnings conference call or presentation 13-Nov-18 4:00pm GMT
  7. Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC — Emerging Consolidated Expectations, Analyst Ratings
  8. Here’s What Palatin Technologies Inc’s (NYSEMKT:PTN) P/E Ratio Is Telling Us
  9. What Kind Of Shareholders Own Palatin Technologies Inc (NYSEMKT:PTN)?
  10. Palatin Technologies, Inc. Reports First Fiscal Quarter 2019 Results and Provides Corporate Update
  11. Why Palatin Technologies Inc (NYSEMKT:PTN) Looks Like A Quality Company
  12. Palatin Technologies, Inc. Announces First-in-Human Study Results of Subcutaneous Administration of PL-8177, An Investigational Melanocortin Receptor 1 Agonist
  13. Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on November 13, 2018
  14. Earnings Preview: Palatin (PTN) Q1 Earnings Expected to Decline
  15. Edited Transcript of PTN earnings conference call or presentation 13-Sep-18 3:00pm GMT
  16. Should You Be Tempted To Buy Poltronic SA (WSE:PTN) Because Of Its PE Ratio?
  17. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results
  18. Palatin Technologies Inc (NYSEMKT:PTN): Risks You Need To Consider Before Buying
  19. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2018 Results; Teleconference and Webcast to be held on September 13, 2018

SEC Filings

  1. EFFECT - Notice of Effectiveness 19600278
  2. 424B5 - Prospectus [Rule 424(b)(5)] 19597738
  3. 424B3 - Prospectus [Rule 424(b)(3)] 19597308
  4. 8-K - Current report 19587706
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 19585824
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 19576359
  7. S-3/A [Amend] - Registration statement under Securities Act of 1933 19568324
  8. 8-K - Current report 19512190
  9. 8-K - Current report 181175123
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173511